Wednesday, October 7, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 17, 2026

Coca-Cola Europacific Partners Q4 Earnings Call Highlights

View original at finance.yahoo.com
Coca-Cola Europacific Partners Q4 Earnings Call Highlights Coca-Cola Europacific Partners logo Key Points CCEP delivered a record 2025 with EUR 20.9 billion revenue, EUR 2.8 billion operating profit, EUR 4.11 EPS, just over EUR 1.8 billion free cash flow, and returned EUR 1.9 billion to shareholders (including a EUR 2…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Company expects mix of 2026 revenue growth to be roughly evenly split among volume, mix, and price

    80% confidence
  • Promotional spend is a huge amount of money with meaningful impact on performance, focus shifting from quantity to effectiveness

    80% confidence
  • France was affected by sugar tax increase on Coca-Cola Classic but performance was stronger than expected

    80% confidence
  • Indonesia distributor base has grown to 182 partners across 300 distribution points with sales force of more than 1,700 people, early results are encouraging

    80% confidence
  • Energy category expected to maintain mid-teens growth cadence over multi-year period

    80% confidence
  • Great Britain had a fantastic year with revenue up almost 6% and volume growth in both channels

    80% confidence
  • Company is approximately 80% hedged on commodities for 2026 full year

    80% confidence
  • Indonesia expected to grow in volume and revenue in 2026 but company has not materially reflected significant upside in guidance

    80% confidence
  • Company expects modest increase in annual interest expense as it refinances roughly EUR 1 billion per year while maintaining weighted average cost of debt around 2.5%

    80% confidence
  • Net debt to EBITDA just below 2.7x, within 2.5-3.0x guidance range

    80% confidence
  • Indonesia zero-sugar sparkling mix rose from 3% to 7%

    80% confidence
  • Zero-sugar products grew around 6% and gained market share in key categories

    80% confidence
  • Indonesia NARTD volumes excluding water were down double digits but second half improved

    80% confidence
  • Germany first half was difficult due to higher promotional shelf prices crossing consumer thresholds

    80% confidence
  • Monster volumes were up nearly 20% in 2025 and drove share gains

    80% confidence
  • Current productivity program is targeting EUR 350-400 million of savings by 2028 and is on track

    80% confidence
  • Coke Zero grew 20% in Philippines last year

    80% confidence
  • More than a third of revenue per case improvement came from brand and pack mix

    80% confidence
  • Philippines delivered strong year with 3% revenue growth, 77% sparkling value share record, and EBIT margin expansion of around 150 basis points toward 10% target

    80% confidence
  • 2025 was another strong year with record revenue, profit, free cash flow, and returns

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
Coca-Cola Europacific Partners Q4 Earnings Call Highlights — Source | Via News | ViaNews Market